JP6367581B2 - 動脈瘤縮小剤 - Google Patents
動脈瘤縮小剤 Download PDFInfo
- Publication number
- JP6367581B2 JP6367581B2 JP2014055499A JP2014055499A JP6367581B2 JP 6367581 B2 JP6367581 B2 JP 6367581B2 JP 2014055499 A JP2014055499 A JP 2014055499A JP 2014055499 A JP2014055499 A JP 2014055499A JP 6367581 B2 JP6367581 B2 JP 6367581B2
- Authority
- JP
- Japan
- Prior art keywords
- aneurysm
- cilostazol
- group
- reducing agent
- shows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Prostheses (AREA)
Description
(1) シロスタゾール又はその薬学的に許容される塩を有効成分とし、内挿されたステントグラフトにより瘤内部への血液の流入が遮断された動脈瘤を縮小することを特徴とする、動脈瘤縮小剤。
(2) 1日当たりの投与量が、シロスタゾール換算で50〜300mgである、前記(1)の動脈瘤縮小剤。
腹部大動脈瘤にEVARを施行した患者94名をランダムに2群に分け、一方の群にシロスタゾールを投与し(シロスタゾール群)、他方の群にはシロスタゾールを投与せず(非シロスタゾール群)、2年間、エンドリークの有無、動脈瘤の大きさ、血液中の脂質(中性脂肪(TG)、総コレステロール(T−Chol)、高密度リポタンパク質(HDL)、低密度リポタンパク質(LDL))について経過観察を行った。なお、当該試験は、国立大学法人浜松医科大学の倫理委員会の承認を得て、予め試験内容の説明を行って試験参加の同意を得た患者に対して行った。各群の患者背景を表1に示す。各群の患者背景には特段の差はなかった。
Claims (2)
- シロスタゾール又はその薬学的に許容される塩を有効成分とし、内挿されたステントグラフトにより瘤内部への血液の流入が遮断された動脈瘤を縮小することを特徴とする、動脈瘤縮小剤。
- 1日当たりの投与量が、シロスタゾール換算で50〜300mgである、請求項1に記載の動脈瘤縮小剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014055499A JP6367581B2 (ja) | 2014-03-18 | 2014-03-18 | 動脈瘤縮小剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014055499A JP6367581B2 (ja) | 2014-03-18 | 2014-03-18 | 動脈瘤縮小剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018128554A Division JP6660053B2 (ja) | 2018-07-05 | 2018-07-05 | エンドリーク発生防止剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015178460A JP2015178460A (ja) | 2015-10-08 |
JP6367581B2 true JP6367581B2 (ja) | 2018-08-01 |
Family
ID=54262796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014055499A Active JP6367581B2 (ja) | 2014-03-18 | 2014-03-18 | 動脈瘤縮小剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6367581B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019054432A1 (ja) * | 2017-09-13 | 2019-03-21 | 国立大学法人浜松医科大学 | 大動脈瘤の治療用医薬組成物 |
WO2020184703A1 (ja) * | 2019-03-13 | 2020-09-17 | 国立大学法人浜松医科大学 | 大動脈瘤の治療用医薬組成物 |
-
2014
- 2014-03-18 JP JP2014055499A patent/JP6367581B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2015178460A (ja) | 2015-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7082115B2 (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
AU2006295440A1 (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients | |
JP2010518169A (ja) | 心血管疾患の処置のためのラノラジンの使用 | |
KR102175622B1 (ko) | 마이봄 기능부전의 치료제 | |
US20080248112A1 (en) | Use of ranolazine for the treatment of coronary microvascular diseases | |
US8957071B2 (en) | Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors | |
CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
JP6367581B2 (ja) | 動脈瘤縮小剤 | |
US20130209584A1 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
JP2011511844A (ja) | 心血管疾患の処置のためのラノラジンの使用 | |
CN102600146B (zh) | 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法 | |
JP2020525436A (ja) | 胃耐性制御放出経口剤形 | |
KR100443891B1 (ko) | 당뇨병성합병증의예방·치료제 | |
JP2018150382A (ja) | エンドリーク発生防止剤 | |
US20040138231A1 (en) | Pharmaceutical composition which comprise a solid dispersion of a hydroxypropyl-methylcellulose phthalate polymer | |
WO2022182982A1 (en) | Methods for treating c-kit kinase mediated diseases and disorders using a selective c-kit kinase inhibitor | |
EP4082549A1 (en) | Drug for preventing dialysis shift or renal death | |
EP2568982B1 (en) | Association of xanthine oxidase inhibitors and angiotensin ii receptor antagonists and use thereof | |
JP2007513991A (ja) | メタボリック症候群の処置のためのスタチンの使用 | |
US20220265686A1 (en) | Fospropofol methods and compositions | |
KR20130074808A (ko) | 스타틴계 지질저하제에 의한 근육계 부작용의 치료 또는 예방을 위한 로사르탄을 포함하는 약제학적 조성물 | |
WO2022048618A1 (en) | Methods to treat inflammatory bowel disease | |
US20220151938A1 (en) | Tablet for use in treating huntington's disease and method of making the same | |
WO2018192469A1 (en) | Inhibitors of fabp4 and methods of treating arthritis | |
AU2021379692A1 (en) | Tablet for use in treating huntington's disease and method of making the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170215 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180327 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180326 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180705 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6367581 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |